Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 6/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | USP14 | P54578 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30371406 | 0.89 | KCNA3 (0.60) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL26665267 | 0.87 | KCNA3 (0.57) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL12971748 | 0.87 | KCNA3 (0.57) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL619386 | 0.87 | KCNA3 (0.57) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL915957 | 0.85 | KCNA3 (0.56) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL913264 | 0.85 | KCNA3 (0.56) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL26814105 | 0.85 | KCNA3 (0.56) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL7222795 | 0.85 | KCNA3 (0.56) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL913704 | 0.85 | KCNA3 (0.56) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL3108831 | 0.85 | KCNA3 (0.56) | KCNA3CTSKDRD2CCR5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | KCNA3 2455/4885CTSK 4784/4885DRD2 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.